The impact of SMYD3 inhibitors on growth of breast cancer cells was tested by adding 50, 100 and 200 μM of Inhibitor-4 or BCI-121 to breast cancer cell lines (MCF7 and MDA-MB-231) and normal breast epithelial cell line (MCF10A). Here, SMYD3 is linked to breast carcinoma.